Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri(Harvard University), Peter Reichardt(Helios Hospital Bad Saarow), Yoon‐Koo Kang(Asan Medical Center), Jean‐Yves Blay(Centre Léon Bérard), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Hans Gelderblom(Leiden University Medical Center), Peter Hohenberger(University Hospital Heidelberg), Michael Leahy(The Christie NHS Foundation Trust), Margaret von Mehren(Fox Chase Cancer Center), Heikki Joensuu(Helsinki University Hospital), Giuseppe Badalamenti(University of Palermo), Martin E. Blackstein(Mount Sinai Hospital), Axel Le Cesne(Institut Gustave Roussy), Patrick Schöffski(KU Leuven), Robert G. Maki(Icahn School of Medicine at Mount Sinai), Sebastian Bauer(University of Duisburg-Essen), Binh Bui Nguyen(Institut Bergonié), Jianming Xu(Academy of Military Medical Sciences), Toshirou Nishida(Osaka Police Hospital), John Chung(Bayer (United States)), Christian Kappeler(Bayer (Germany)), Iris Kuss(Bayer (Germany)), Dirk Laurent(Bayer (Germany)), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 1,399Open Access
Abstract
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Charles D. Blanke et al.|New England Journal of Medicine|2002|4.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu et al.|Journal of the National Comprehensive Cancer Network|2010|1.2k